Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioterrorism conference

This article was originally published in The Gray Sheet

Executive Summary

HHS Secretary Tommy Thompson informs AdvaMed June 20 that he will work with the association's Medical Technology Preparedness Council to plan a day-long seminar on priority countermeasures in September to inform industry reps of the department's activities and "to bring the American people more up to date with how far we've progressed." AdvaMed's emergency team recently proposed surveying manufacturers to develop a list of devices that would potentially be used in response to a biological/chemical attack (1"The Gray Sheet" April 1, 2002, p. 5)...

You may also be interested in...



Device Regulatory Reform Opportunity Presented By Homeland Security Office

Consolidation of federal funding and regulatory pathways for counter-terrorism products is among the benefits of establishing a cabinet-level Department of Homeland Security, according to device industry advocates

FDA Weighing Device Industry Survey For Emergency Response Data

FDA's Center for Devices & Radiological Health is considering creating a list of medical device manufacturers to be contacted in case supply shortages result from a bioterrorist attack

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel